Skip to main content
SpringerLink
Log in
SpringerLink
Log in

The management of bone metastases

  • Chapter
The Teaching Cases from Annals of Oncology

  • 91 Accesses

Abstract

Bone is the most common site of metastatic disease and is especially prevalent in tumours arising in the breast, prostate, lung, thyroid and kidney. Because of the frequency and relatively long course of breast cancer, bone metastases from this site are clinically the most important. The pattern of distribution of bone metastases is similar for most tumours, affecting the spine, pelvis, ribs, skull and proximal femora, and typically more than one site is involved. The prognosis depends fundamentally on the type of the primary tumour. The longest median survivals are seen in prostate [19] and thyroid cancers (more than 3 years), compared with two years for breast cancer [4] and multiple myeloma, and only a few months for melanoma and lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bross P, Reynders P, Vanderschot P. Surgical treatment of the metastatic fracture of the femur improves quality of life. Acta Orthop Belg 1993; 59(Suppl 1):52–6.

    Google Scholar 

  2. Bundred NJ, Ratcliffe WA, Walker RA et al. Parathyroid hormone-related protein and hypercalcaemia in breast cancer. BMJ 1991; 303:1506–9.

    Article  CAS  PubMed  Google Scholar 

  3. Coleman R, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 1993; 79–103.

    Google Scholar 

  4. Coleman R, Rubens R. The clinical course of metastases from breast cancer. Br J Cancer 1987a; 55:61–6.

    Article  CAS  PubMed  Google Scholar 

  5. Coleman R, Rubens R. Treatment of hypercalcaemia of malignancy secondary to advanced breast cancer with 3 (amino-1, lhydroxypropyledene) bisphosphonate. Br J Cancer 1987b; 56:465–9.

    Article  CAS  PubMed  Google Scholar 

  6. Coleman R. Clinical aspects of metastatic disease. InColeman R, Rubens R (eds): Metastatic Bone Disease. The Partenon Publishing Group, Lancs 1992; 11–25.

    Google Scholar 

  7. Conte PF, Giannessi PG, Latreille J et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: A randomised, multicenter phase III trial. Ann Oncol 1994;5(Suppl7): S41–S4.

    Google Scholar 

  8. Dauggard G. Tamoxifen and hypercalcaemia. Ann Oncol 1993; 4:683–7.

    Google Scholar 

  9. Flanagan AM, Chambers TJ. Clodronate inhibits resorption through injury of osteoclast that resorbs clodronate coated bone. Bone Miner 1989; 6:33–43.

    Article  CAS  PubMed  Google Scholar 

  10. Fleisch H. Pharmacokinetics of bisphosphonates. InFleisch H (ed): Bisphosphonates in Bone Disease. Berne: Stamplfi Co. Ltd. 1993; 50–4.

    Google Scholar 

  11. Galasko SB. The role of the orthopaedic surgeon in the treatment of skeletal metastases. InRubens R, Fogelman I (eds): Bone Metastases — Diagnosis and Treatment. London: Springer-Verlag 1991; 207–22.

    Google Scholar 

  12. Grutters JC, Hermus AR, De Muller PH, Beex LV. Long-term follow-up of breast cancer patients treated for hypercalcaemia with APD. Breast Cancer Res Treat 1993; 25(3):277–81.

    Article  CAS  PubMed  Google Scholar 

  13. Gucalp R, Ritch P, Weirnik PH et al. Comparative study of pamidronate and etidronate in the treatment of cancer-related hypercalcaemia. J Clin Oncol 1992; 10:134–42.

    CAS  PubMed  Google Scholar 

  14. Hoskin PJ, Price P, Easton B et al. A prospective randomised trial of 4 cGy or 8 cGy single doses in the treatment of metastatic bone pain. Radiother Oncol 1992; 23:74–8.

    Article  CAS  PubMed  Google Scholar 

  15. Louviax I, Dumon JC, Body JJ. Efficacy of pamidronate for recurrences of tumor-induced hypercalcaemia according to the tumour type. Second Workshop on Bisphosphonates, 1994, Abstr 73.

    Google Scholar 

  16. Lowik CWGM, Van der Pluijm G, Bijvoet OLM. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts; the effects of a bisphosphonate. J Bone Miner Res 1988; 3:185–92.

    Article  CAS  PubMed  Google Scholar 

  17. Mundy G. Metastatic bone disease. InMundy G (ed): Bone Remodelling and Its Disorders. London: Martin Dunitz 1995; 104–22.

    Google Scholar 

  18. Mireis H. Metastatic disease in long bones. A proposed scoring system. Clin Orthop 1989; 249:256–65.

    Google Scholar 

  19. Nesbit RM, Baum WC. Endocrine control of prostatic carcinoma: Clinical and statistical survey of 1818 cases. JNCI 1984; 68:507–17.

    Google Scholar 

  20. Nussbaum SR, Younger J, Vanderpol CJ et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcaemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95(3):297–304.

    Article  CAS  PubMed  Google Scholar 

  21. Paterson AHG, Powels TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases with breast cancer. J Clin Oncol 1993; 11:59–65.

    CAS  PubMed  Google Scholar 

  22. Pigott KH, Baddely H, Matter EJ. Pattern of disease in spinal cord compression on MRI scan and implications for treatment. Clin Oncol R Coll 1994; 6(1):7–10.

    Article  CAS  Google Scholar 

  23. Price P, Hoskin PJ, Easton D et al. Low-dose single-fraction radiotherapy in the treatment of metastatic bone pain. Radiother Oncol 1988; 12:297–300.

    Article  CAS  PubMed  Google Scholar 

  24. Purohit OP, Anthony C, Owen J et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994; 70:554–8.

    Article  CAS  PubMed  Google Scholar 

  25. Purohit OP, Anthony C, Owen J et al. Randomised double-blind comparison of single infusions of pamidronate or clodronate for hypercalcaemia of malignancy. Br J Cancer 1994; 69(Suppl XXI):10.

    Google Scholar 

  26. Ralston S, Gallacher SJ, Dryburgh FJ et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; ii:1180–3.

    Google Scholar 

  27. Strewler GJ, Nissenson RA. Parathyroid hormone-related protein. In Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. New York: Raven Press 1993; 61–3.

    Google Scholar 

  28. Thiebaud D, Jaeger P, Burckhardt P. Fast and effective treatment of malignant hypercalcaemia with combined pamidronate and calcitonin. BMJ 1990; 292:1549–50.

    Google Scholar 

  29. Thurlimann B, Waldburger R, Senn HJ et al. Plicamycin and pamidronate in symptomatic tumour-related hypercalcaemia: A prospective randomised cross-over trial. Ann Oncol 1992; 3:619–23.

    CAS  PubMed  Google Scholar 

  30. Tyrrell CJ on behalf of the Aredia Multinational Cooperative Group. Role of pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial. Ann Oncol 1994; 5 (Suppl 7):37–40.

    Google Scholar 

  31. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11(3):491–8.

    PubMed  Google Scholar 

  32. Warrell RP, Heller G, Murphy WP et al. A randomised double-blind study of gallium nitrate compared to etidronate for acute control of hypercalcaemia. J Clin Oncol 1991; 9:1467–75.

    PubMed  Google Scholar 

  33. Wimalawansa SJ. Significance of plasma PTH-rP in patients with hypercalcaemia of malignancy treated with bisphosphonate. Cancer 1994; 73(8):223–30.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. YCRC Department of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK

    J. Vinholes & R. Coleman

Authors
  1. J. Vinholes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology, University College London Medical School, The Middlesex Hospital, London, UK

    R. L. Souhami

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Vinholes, J., Coleman, R. (1997). The management of bone metastases. In: Souhami, R.L. (eds) The Teaching Cases from Annals of Oncology. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5456-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5456-7_6

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-0-7923-4117-8

  • Online ISBN: 978-94-011-5456-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation